Cargando…

METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer

BACKGROUND: N6-methyladenosine (m6A) methylation is the most abundant chemical posttranscriptional modification of mRNA, and it is associated with the regulation of the immune response to tumors. However, the function of m6A modification in the immune response to endometrial cancer (EC) remains unkn...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Lei, Zhang, Jing, Zhang, Jun-Hui, Liu, Xiao-Jing, Guo, Bao, Chen, Jia-Hua, Tang, Zhen-Hai, Wang, Wen-Yan, Wang, Qing-Yuan, Wei, Bing, Cao, Yun-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122371/
https://www.ncbi.nlm.nih.gov/pubmed/37085864
http://dx.doi.org/10.1186/s40364-023-00479-4
_version_ 1785029478546669568
author Zhan, Lei
Zhang, Jing
Zhang, Jun-Hui
Liu, Xiao-Jing
Guo, Bao
Chen, Jia-Hua
Tang, Zhen-Hai
Wang, Wen-Yan
Wang, Qing-Yuan
Wei, Bing
Cao, Yun-Xia
author_facet Zhan, Lei
Zhang, Jing
Zhang, Jun-Hui
Liu, Xiao-Jing
Guo, Bao
Chen, Jia-Hua
Tang, Zhen-Hai
Wang, Wen-Yan
Wang, Qing-Yuan
Wei, Bing
Cao, Yun-Xia
author_sort Zhan, Lei
collection PubMed
description BACKGROUND: N6-methyladenosine (m6A) methylation is the most abundant chemical posttranscriptional modification of mRNA, and it is associated with the regulation of the immune response to tumors. However, the function of m6A modification in the immune response to endometrial cancer (EC) remains unknown. Our study investigated the immunological role of methyltransferase-like 3 (METTL3) in EC and the underlying molecular mechanism. METHODS: We investigated the correlation between the expression of METTL3 and CD8 by using an endometrial tissue microarray cohort. Next, we investigated the role and mechanism of METTL3 in the immune response to EC using a mouse tumor model and a CD8(+) T cell-EC cell coculture system after METTL3 overexpression or depletion. Additionally, RNA immunoprecipitation (RIP), methylated RIP, and RNA stability experiments were used to investigate the mechanism underlying the function of METTL3 in immunosurveillance of EC. RESULTS: METTL3 levels were downregulated in EC patients, low levels of METTL3 were correlated with poor prognosis in EC patients. There was a positive correlation between METTL3 expression and CD8 expression. Overexpression of METTL3 in the EC cell and CD8(+) T cell coculture system inhibited EC cell proliferation, migration, and promoted CD8(+) T-cell proliferation, and in vivo, METTL3 overexpression increased CD8(+) T cell proportions and inhibited EC progression; however, genetic depletion of METTL3 exerted the opposite effects. NLR family CARD domain-containing 5 (NLRC5) was identified as a target of METTL3-mediated m6A modification. The degradation of NLRC5 was increased by YTH domain-containing family 2 (YTHDF2). CONCLUSIONS: Overall, METTL3, YTHDF2, and NLRC5 have potential to be the diagnostic and prognostic biomarkers for EC. METTL3 facilitated the m6A modifications of NLRC5 and inhibited its degradation through a YTHDF2-dependent mechanism in EC. Genetic overexpression of METTL3 attenuated the immune evasion of EC by promoting NLRC5-mediated immunosurveillance, suggesting that the METTL3/YTHDF2/NLRC5 axis is a promising target of immunotherapy in EC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-023-00479-4.
format Online
Article
Text
id pubmed-10122371
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101223712023-04-23 METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer Zhan, Lei Zhang, Jing Zhang, Jun-Hui Liu, Xiao-Jing Guo, Bao Chen, Jia-Hua Tang, Zhen-Hai Wang, Wen-Yan Wang, Qing-Yuan Wei, Bing Cao, Yun-Xia Biomark Res Correspondence BACKGROUND: N6-methyladenosine (m6A) methylation is the most abundant chemical posttranscriptional modification of mRNA, and it is associated with the regulation of the immune response to tumors. However, the function of m6A modification in the immune response to endometrial cancer (EC) remains unknown. Our study investigated the immunological role of methyltransferase-like 3 (METTL3) in EC and the underlying molecular mechanism. METHODS: We investigated the correlation between the expression of METTL3 and CD8 by using an endometrial tissue microarray cohort. Next, we investigated the role and mechanism of METTL3 in the immune response to EC using a mouse tumor model and a CD8(+) T cell-EC cell coculture system after METTL3 overexpression or depletion. Additionally, RNA immunoprecipitation (RIP), methylated RIP, and RNA stability experiments were used to investigate the mechanism underlying the function of METTL3 in immunosurveillance of EC. RESULTS: METTL3 levels were downregulated in EC patients, low levels of METTL3 were correlated with poor prognosis in EC patients. There was a positive correlation between METTL3 expression and CD8 expression. Overexpression of METTL3 in the EC cell and CD8(+) T cell coculture system inhibited EC cell proliferation, migration, and promoted CD8(+) T-cell proliferation, and in vivo, METTL3 overexpression increased CD8(+) T cell proportions and inhibited EC progression; however, genetic depletion of METTL3 exerted the opposite effects. NLR family CARD domain-containing 5 (NLRC5) was identified as a target of METTL3-mediated m6A modification. The degradation of NLRC5 was increased by YTH domain-containing family 2 (YTHDF2). CONCLUSIONS: Overall, METTL3, YTHDF2, and NLRC5 have potential to be the diagnostic and prognostic biomarkers for EC. METTL3 facilitated the m6A modifications of NLRC5 and inhibited its degradation through a YTHDF2-dependent mechanism in EC. Genetic overexpression of METTL3 attenuated the immune evasion of EC by promoting NLRC5-mediated immunosurveillance, suggesting that the METTL3/YTHDF2/NLRC5 axis is a promising target of immunotherapy in EC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40364-023-00479-4. BioMed Central 2023-04-21 /pmc/articles/PMC10122371/ /pubmed/37085864 http://dx.doi.org/10.1186/s40364-023-00479-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Zhan, Lei
Zhang, Jing
Zhang, Jun-Hui
Liu, Xiao-Jing
Guo, Bao
Chen, Jia-Hua
Tang, Zhen-Hai
Wang, Wen-Yan
Wang, Qing-Yuan
Wei, Bing
Cao, Yun-Xia
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
title METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
title_full METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
title_fullStr METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
title_full_unstemmed METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
title_short METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer
title_sort mettl3 facilitates immunosurveillance by inhibiting ythdf2-mediated nlrc5 mrna degradation in endometrial cancer
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122371/
https://www.ncbi.nlm.nih.gov/pubmed/37085864
http://dx.doi.org/10.1186/s40364-023-00479-4
work_keys_str_mv AT zhanlei mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT zhangjing mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT zhangjunhui mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT liuxiaojing mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT guobao mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT chenjiahua mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT tangzhenhai mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT wangwenyan mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT wangqingyuan mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT weibing mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer
AT caoyunxia mettl3facilitatesimmunosurveillancebyinhibitingythdf2mediatednlrc5mrnadegradationinendometrialcancer